Where are you at today with the, the technology?

Yeah.

So, so, so the, the, the product that we're building right now, we're, we're building the first diagnostic and severity monitoring platform for behavioral health, and our initial focus is on PTSD, anxiety, and depression.

And the, you know, the, the-- There have been a lot of previous attempts to kinda try and quantify mental health, and besides for the technology, which I'll explain in a second, the, the biggest way that we differentiate ourselves from a lot of previous attempts is that we really don't think you can change the clinical journey, or by that, the outcomes of patients, unless you can establish a real gold standard in the space.

And so we are purposely pursuing, you know, a, a regulatory path through the FDA as a diagnostic for all the indication that we're focused on, which is not to say you can't use it as a screening tool.

But we think it's very important that, like, we hit the bar of this is a diagnostic in the eyes of the FDA.

So the, the way the product works, the first time a patient interacts with it, it's a roughly 10-and-a-half minute test.

Hmm